Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis (NCT07674134) | Clinical Trial Compass
RecruitingNot Applicable
Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Monaco90 participantsStarted 2024-04-23
Plain-language summary
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.
The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient aged over 18 years
* Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria
* Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations
* Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.
Exclusion Criteria:
* No contraindication to a bDMARD
* Not stable dose of corticosteroids in the 4 weeks preceding enrollment
* Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment
* Prior treatment with a JAK inhibitor
* Patient unable to be followed-up in the study during 6 months
* Minors or adults under guardianship or curatorship, or deprived of their liberty
* Pregnant or breastfeeding patient
* Patient refusing to use an effective method of contraception for the duration of the study
* Person not affiliated with a social security scheme.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.